PLOS ONE, vol.9, no.1, 2014 (SCI-Expanded)
Objectives: Both caspofungin and voriconazole were initially approved by the FDA with very narrow indications. Our aim was to evaluate the utilization patterns and comparative effectiveness of these agents early after marketing before any labeling change occurred.